Literature DB >> 29883661

Neural crest state activation in NRAS driven melanoma, but not in NRAS-driven melanocyte expansion.

Alicia M McConnell1, Jeffrey K Mito2, Julien Ablain1, Michelle Dang1, Luke Formichella1, David E Fisher3, Leonard I Zon4.   

Abstract

NRAS mutations are frequently found in many deadly malignancies and are the second most common oncogene driving malignant melanoma. Here, we generate a rapid transient transgenic zebrafish model of NRASQ61R-mutant melanoma. These fish develop extensive melanocytic proliferation in approximately 4 weeks. The majority of these lesions do not engraft upon transplantation and lack overt histologic features of malignancy. Our previous work demonstrated that activation of a neural crest cell transcriptional program is a key initiating event in zebrafish BRAF/p53-driven melanomas using the fluorescent reporter crestin:EGFP. By 8-12 weeks of age, some lesions progress to malignant melanoma and have cytologic atypia, destructive tissue invasion, and express neural crest progenitor markers, including crestin:EGFP. Our studies demonstrate that NRASQ61R induces extensive melanocyte expansion, which arise during zebrafish development and lack a transformed phenotype. These early lesions are highly predisposed to reactivate a neural crest progenitor fate and form malignant melanomas.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Melanoma; NRAS; Neural crest

Mesh:

Substances:

Year:  2018        PMID: 29883661      PMCID: PMC6281797          DOI: 10.1016/j.ydbio.2018.05.026

Source DB:  PubMed          Journal:  Dev Biol        ISSN: 0012-1606            Impact factor:   3.582


  21 in total

1.  NRAS mutation status is an independent prognostic factor in metastatic melanoma.

Authors:  John A Jakob; Roland L Bassett; Chaan S Ng; Jonathan L Curry; Richard W Joseph; Gladys C Alvarado; Michelle L Rohlfs; Jessie Richard; Jeffrey E Gershenwald; Kevin B Kim; Alexander J Lazar; Patrick Hwu; Michael A Davies
Journal:  Cancer       Date:  2011-12-16       Impact factor: 6.860

Review 2.  Melanoma risk in congenital melanocytic naevi: a systematic review.

Authors:  S Krengel; A Hauschild; T Schäfer
Journal:  Br J Dermatol       Date:  2006-07       Impact factor: 9.302

3.  The Tol2kit: a multisite gateway-based construction kit for Tol2 transposon transgenesis constructs.

Authors:  Kristen M Kwan; Esther Fujimoto; Clemens Grabher; Benjamin D Mangum; Melissa E Hardy; Douglas S Campbell; John M Parant; H Joseph Yost; John P Kanki; Chi-Bin Chien
Journal:  Dev Dyn       Date:  2007-11       Impact factor: 3.780

4.  NRAS mutation is the sole recurrent somatic mutation in large congenital melanocytic nevi.

Authors:  Christelle Charbel; Romain H Fontaine; Gabriel G Malouf; Arnaud Picard; Natacha Kadlub; Nizar El-Murr; Alexandre How-Kit; Xiaoping Su; Aurore Coulomb-L'Hermine; Jorg Tost; Samia Mourah; Selim Aractingi; Sarah Guégan
Journal:  J Invest Dermatol       Date:  2013-10-15       Impact factor: 8.551

5.  Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.

Authors:  Bianca Devitt; Wendy Liu; Renato Salemi; Rory Wolfe; John Kelly; Chin-Yuan Tzen; Alexander Dobrovic; Grant McArthur
Journal:  Pigment Cell Melanoma Res       Date:  2011-06-22       Impact factor: 4.693

Review 6.  Treatment of NRAS-mutant melanoma.

Authors:  Douglas B Johnson; Igor Puzanov
Journal:  Curr Treat Options Oncol       Date:  2015-04

7.  Cancer statistics, 2016.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2016-01-07       Impact factor: 508.702

8.  Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.

Authors:  Reinhard Dummer; Dirk Schadendorf; Paolo A Ascierto; Ana Arance; Caroline Dutriaux; Anna Maria Di Giacomo; Piotr Rutkowski; Michele Del Vecchio; Ralf Gutzmer; Mario Mandala; Luc Thomas; Lev Demidov; Claus Garbe; David Hogg; Gabriella Liszkay; Paola Queirolo; Ernesto Wasserman; James Ford; Marine Weill; L Andres Sirulnik; Valentine Jehl; Viviana Bozón; Georgina V Long; Keith Flaherty
Journal:  Lancet Oncol       Date:  2017-03-09       Impact factor: 41.316

9.  Transparent adult zebrafish as a tool for in vivo transplantation analysis.

Authors:  Richard Mark White; Anna Sessa; Christopher Burke; Teresa Bowman; Jocelyn LeBlanc; Craig Ceol; Caitlin Bourque; Michael Dovey; Wolfram Goessling; Caroline Erter Burns; Leonard I Zon
Journal:  Cell Stem Cell       Date:  2008-02-07       Impact factor: 24.633

10.  A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation.

Authors:  Charles K Kaufman; Christian Mosimann; Zi Peng Fan; Song Yang; Andrew J Thomas; Julien Ablain; Justin L Tan; Rachel D Fogley; Ellen van Rooijen; Elliott J Hagedorn; Christie Ciarlo; Richard M White; Dominick A Matos; Ann-Christin Puller; Cristina Santoriello; Eric C Liao; Richard A Young; Leonard I Zon
Journal:  Science       Date:  2016-01-28       Impact factor: 47.728

View more
  9 in total

Review 1.  Neural crest lineage analysis: from past to future trajectory.

Authors:  Weiyi Tang; Marianne E Bronner
Journal:  Development       Date:  2020-10-23       Impact factor: 6.868

Review 2.  Zebrafish patient avatars in cancer biology and precision cancer therapy.

Authors:  Maurizio Fazio; Julien Ablain; Yan Chuan; David M Langenau; Leonard I Zon
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

3.  Recurrent co-alteration of HDGF and SETDB1 on chromosome 1q drives cutaneous melanoma progression and poor prognosis.

Authors:  Maurizio Fazio; Ellen van Rooijen; Jeffrey K Mito; Rodsy Modhurima; Erika Weiskopf; Song Yang; Leonard I Zon
Journal:  Pigment Cell Melanoma Res       Date:  2020-11-17       Impact factor: 4.693

4.  Stage-dependent differential gene expression profiles of cranial neural crest-like cells derived from mouse-induced pluripotent stem cells.

Authors:  Ayano Odashima; Shoko Onodera; Akiko Saito; Yuuki Ogihara; Tatsuya Ichinohe; Toshifumi Azuma
Journal:  Med Mol Morphol       Date:  2019-07-11       Impact factor: 2.309

Review 5.  From Tank to Treatment: Modeling Melanoma in Zebrafish.

Authors:  William Tyler Frantz; Craig J Ceol
Journal:  Cells       Date:  2020-05-22       Impact factor: 6.600

6.  SATB2 induction of a neural crest mesenchyme-like program drives melanoma invasion and drug resistance.

Authors:  Maurizio Fazio; Ellen van Rooijen; Michelle Dang; Glenn van de Hoek; Julien Ablain; Jeffrey K Mito; Song Yang; Andrew Thomas; Jonathan Michael; Tania Fabo; Rodsy Modhurima; Patrizia Pessina; Charles K Kaufman; Yi Zhou; Richard M White; Leonard I Zon
Journal:  Elife       Date:  2021-02-02       Impact factor: 8.140

Review 7.  Reemergence of neural crest stem cell-like states in melanoma during disease progression and treatment.

Authors:  Johanna Diener; Lukas Sommer
Journal:  Stem Cells Transl Med       Date:  2020-12-01       Impact factor: 6.940

Review 8.  Zebrafish Models to Study the Crosstalk between Inflammation and NADPH Oxidase-Derived Oxidative Stress in Melanoma.

Authors:  Irene Pardo-Sánchez; Diana García-Moreno; Victoriano Mulero
Journal:  Antioxidants (Basel)       Date:  2022-06-28

9.  Regulation of zebrafish melanocyte development by ligand-dependent BMP signaling.

Authors:  Alec K Gramann; Arvind M Venkatesan; Melissa Guerin; Craig J Ceol
Journal:  Elife       Date:  2019-12-23       Impact factor: 8.140

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.